Tina Vilsboll

Summary

Affiliation: University of Copenhagen
Country: Denmark

Publications

  1. doi request reprint Liraglutide: a new treatment for type 2 diabetes
    Tina Vilsboll
    Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
    Drugs Today (Barc) 45:101-13. 2009
  2. doi request reprint Non-glycaemic effects mediated via GLP-1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide
    T Vilsbøll
    Diabetes Research Division, Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark
    Diabetes Obes Metab 14:41-9. 2012
  3. pmc Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials
    Tina Vilsbøll
    Diabetes Research Division, Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, DK 2900 Hellerup, Denmark
    BMJ 344:d7771. 2012
  4. ncbi request reprint Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus
    Tina Vilsbøll
    Gentofte Hospital, Department of Internal Medicine F, University of Copenhagen, Niels Andersens Vej 65, DK 2900 Hellerup, Denmark
    Expert Opin Investig Drugs 16:231-7. 2007
  5. ncbi request reprint Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes
    Tina Vilsbøll
    Department of Internal Medicine, Gentofte Hospital, Hellerup, Denmark
    Diabetes Care 30:1608-10. 2007
  6. ncbi request reprint [Effect of incretin hormones GIP and GLP-1 for the pathogenesis of type 2 diabetes mellitus]
    Tina Vilsbøll
    Gentofte Hospital, Medicinsk afdeling F, Hellerup
    Ugeskr Laeger 169:2101-5. 2007
  7. doi request reprint Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus
    T Vilsbøll
    Department of Internal Medicine F, Gentofte Hospital, Gentofte, Denmark
    Diabet Med 25:152-6. 2008
  8. ncbi request reprint Long-acting GLP-1 analogs for the treatment of type 2 diabetes mellitus
    Tina Vilsbøll
    Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark
    BioDrugs 22:251-7. 2008
  9. doi request reprint The spectrum of antidiabetic actions of GLP-1 in patients with diabetes
    Tina Vilsbøll
    Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Niels Andersens Vej 65, DK 2900 Hellerup, Denmark
    Best Pract Res Clin Endocrinol Metab 23:453-62. 2009
  10. ncbi request reprint The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects
    Tina Vilsbøll
    Department of Internal Medicine F, Gentofte Hospital, Denmark
    Regul Pept 137:168-72. 2006

Collaborators

Detail Information

Publications49

  1. doi request reprint Liraglutide: a new treatment for type 2 diabetes
    Tina Vilsboll
    Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
    Drugs Today (Barc) 45:101-13. 2009
    ..It is expected to be approved by the U.S. Food and Drug Administration and the European Medicines Agency in Europe for use in 2009...
  2. doi request reprint Non-glycaemic effects mediated via GLP-1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide
    T Vilsbøll
    Diabetes Research Division, Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark
    Diabetes Obes Metab 14:41-9. 2012
    ..These effects and other safety aspects of GLP-1 therapy are currently being investigated in ongoing long-term clinical studies...
  3. pmc Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials
    Tina Vilsbøll
    Diabetes Research Division, Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, DK 2900 Hellerup, Denmark
    BMJ 344:d7771. 2012
    ..To determine whether treatment with agonists of glucagon-like peptide-1 receptor (GLP-1R) result in weight loss in overweight or obese patients with or without type 2 diabetes mellitus...
  4. ncbi request reprint Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus
    Tina Vilsbøll
    Gentofte Hospital, Department of Internal Medicine F, University of Copenhagen, Niels Andersens Vej 65, DK 2900 Hellerup, Denmark
    Expert Opin Investig Drugs 16:231-7. 2007
    ..This article reviews the mechanisms of action and efficacy of liraglutide for the treatment of Type 2 diabetes mellitus. This agent is presently in Phase III clinical development...
  5. ncbi request reprint Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes
    Tina Vilsbøll
    Department of Internal Medicine, Gentofte Hospital, Hellerup, Denmark
    Diabetes Care 30:1608-10. 2007
  6. ncbi request reprint [Effect of incretin hormones GIP and GLP-1 for the pathogenesis of type 2 diabetes mellitus]
    Tina Vilsbøll
    Gentofte Hospital, Medicinsk afdeling F, Hellerup
    Ugeskr Laeger 169:2101-5. 2007
    ..It is currently unknown whether these defects are consequences of the diabetic state or primary pathogenetic factors...
  7. doi request reprint Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus
    T Vilsbøll
    Department of Internal Medicine F, Gentofte Hospital, Gentofte, Denmark
    Diabet Med 25:152-6. 2008
    ..Glucose effectiveness and insulin sensitivity were estimated by means of the insulin-modified frequently sampled intravenous glucose tolerance test...
  8. ncbi request reprint Long-acting GLP-1 analogs for the treatment of type 2 diabetes mellitus
    Tina Vilsbøll
    Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark
    BioDrugs 22:251-7. 2008
    ....
  9. doi request reprint The spectrum of antidiabetic actions of GLP-1 in patients with diabetes
    Tina Vilsbøll
    Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Niels Andersens Vej 65, DK 2900 Hellerup, Denmark
    Best Pract Res Clin Endocrinol Metab 23:453-62. 2009
    ..GLP-1 also inhibits glucagon secretion and suppresses food intake and appetite...
  10. ncbi request reprint The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects
    Tina Vilsbøll
    Department of Internal Medicine F, Gentofte Hospital, Denmark
    Regul Pept 137:168-72. 2006
    ..The primary metabolite, GIP 3-42, generated through the action of dipeptidyl peptidase IV (DPP-IV), was eliminated with a mean half-life of 17.5 and 20.5 min in patients and healthy subjects (NS)...
  11. doi request reprint The effects of glucagon-like peptide-1 on the beta cell
    T Vilsbøll
    Department of Internal Medicine, Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark
    Diabetes Obes Metab 11:11-8. 2009
    ..Clinical studies are needed to confirm these findings in humans. Replication of these data in humans could have important clinical implications for the treatment of type 2 diabetes...
  12. doi request reprint KATP channel closure ameliorates the impaired insulinotropic effect of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes
    Kasper Aaboe
    Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Niels Andersens Vej 65, Hellerup DK 2900, Denmark
    J Clin Endocrinol Metab 94:603-8. 2009
    ..With this study we therefore aimed at clarifying the role of K(ATP) channel malfunction in the impaired function of GIP...
  13. ncbi request reprint No reactive hypoglycaemia in Type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose
    T Vilsbøll
    Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Denmark
    Diabet Med 18:144-9. 2001
    ..Since GLP-1 is also effective in Type 2 diabetic patients and is presently being evaluated as a therapeutic agent in this disease, it is important to investigate whether GLP-1 can cause hypoglycaemia in such patients...
  14. ncbi request reprint Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus
    T Vilsbøll
    Department of Internal Medicine F, Gentofte Hospital, Hellerup, Denmark
    J Clin Endocrinol Metab 88:2706-13. 2003
    ....
  15. ncbi request reprint The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype
    T Vilsbøll
    Department of Internal Medicine F, Gentofte Hospital, DK 2900 Hellerup, Denmark
    J Clin Endocrinol Metab 88:4897-903. 2003
    ..In conclusion, lack of GIP amplification of the late-phase plasma insulin response to glucose seems to be a consequence of diabetes mellitus, characterizing most, if not all, forms of diabetes...
  16. ncbi request reprint Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects
    Tina Vilsbøll
    Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark
    Regul Pept 114:115-21. 2003
    ....
  17. ncbi request reprint Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients
    T Vilsbøll
    Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Niels Andersens Vej 65, 2900 Hellerup, Denmark
    Diabetologia 45:1111-9. 2002
    ..Our investigation evaluated "early" (protocol 1) - and "late phase" (protocol 2) insulin and C-peptide responses to GLP-1 and GIP stimulation in patients with Type II diabetes...
  18. ncbi request reprint Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients
    T Vilsbøll
    Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Denmark
    Diabetes 50:609-13. 2001
    ....
  19. ncbi request reprint Evaluation of beta-cell secretory capacity using glucagon-like peptide 1
    T Vilsbøll
    Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
    Diabetes Care 23:807-12. 2000
    ..Beta-cell secretory capacity is often evaluated with a glucagon test or a meal test. However, glucagon-like peptide 1 (GLP-1) is the most insulinotropic hormone known, and the effect is preserved in type 2 diabetic patients...
  20. ncbi request reprint Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus
    Mikkel Christensen
    Amager Hospital, Department of Internal Medicine, University of Copenhagen, Denmark
    IDrugs 12:503-13. 2009
    ....
  21. doi request reprint Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetes
    Kristine J Hare
    Department of Internal Medicine F, Gentofte Hospital, The Panum Institute, University of Copenhagen, Denmark
    Am J Physiol Endocrinol Metab 298:E832-7. 2010
    ..g., glucose-dependent insulinotropic polypeptide), in type 1 diabetic hyperglucagonemia...
  22. doi request reprint Impaired regulation of the incretin effect in patients with type 2 diabetes
    Jonatan I Bagger
    Diabetes Research Division, Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, DK 2900 Copenhagen, Denmark
    J Clin Endocrinol Metab 96:737-45. 2011
    ..Whether patients with type 2 diabetes mellitus (T2DM) are able to regulate their incretin effect is unknown...
  23. doi request reprint Preserved inhibitory potency of GLP-1 on glucagon secretion in type 2 diabetes mellitus
    Kristine J Hare
    Department of Biomedical Sciences, The Panum Institute, University of Copenhagen, Blegdamsvej 3, DK 2200 Copenhagen N, Denmark
    J Clin Endocrinol Metab 94:4679-87. 2009
    ..We investigated the dose-response relationship for GLP-1-induced glucagon suppression in patients with type 2 diabetes (T2DM) and healthy controls...
  24. doi request reprint Increased postprandial GIP and glucagon responses, but unaltered GLP-1 response after intervention with steroid hormone, relative physical inactivity, and high-calorie diet in healthy subjects
    Katrine B Hansen
    Department of Clinical Physiology, Glostrup Hospital, University of Copenhagen, Nordre Ringvej 57, DK 2600 Glostrup, Denmark
    J Clin Endocrinol Metab 96:447-53. 2011
    ..The causality of these pathophysiological traits is unknown. We aimed to determine the impact of insulin resistance and reduced glucose tolerance on postprandial GIP, GLP-1, and glucagon responses in healthy subjects...
  25. doi request reprint Glucagon-like peptide-2, but not glucose-dependent insulinotropic polypeptide, stimulates glucagon release in patients with type 1 diabetes
    Mikkel Christensen
    Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Niels Andersens Vej 65, DK 2900 Hellerup, Denmark
    Regul Pept 163:96-101. 2010
    ..In conclusion, GLP-2, but not GIP, was found to stimulate the release of glucagon in patients with T1DM, suggesting a role for GLP-2 in the postprandial hyperglucagonaemia characterising individuals with T1DM...
  26. ncbi request reprint Typical Danish Caucasian type 2 diabetic patients do not commonly carry genetic variants in GIP and GLP-1 encoding regions of the proGIP and proglucagon genes
    Cathrine Ørskov
    Department of Medical Anatomy, The Panum Institute, University of Copenhagen, Blegdamsvej 3C, Copenhagen DK 2200, Denmark
    Regul Pept 119:151-4. 2004
    ..Thus, the aim of this study was to study the occurrence of genetic variants in the GIP and GLP-1 encoding regions of the proGIP and proglucagon genes in type 2 diabetic patients and matched control subjects...
  27. ncbi request reprint Incretin-based therapy of type 2 diabetes mellitus
    Filip K Knop
    Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Niels Andersens Vej 65, Hellerup, Denmark
    Curr Protein Pept Sci 10:46-55. 2009
    ....
  28. doi request reprint Lixisenatide for type 2 diabetes mellitus
    Mikkel Christensen
    University of Copenhagen, Gentofte Hospital, Diabetes Research Division, Department of Internal Medicine F, Hellerup, Denmark
    Expert Opin Investig Drugs 20:549-57. 2011
    ..Glucagon-like peptide-1 (GLP-1) receptor agonists are an expanding drug class that target several of the pathophysiological traits of T2DM. Lixisenatide is a GLP-1 receptor agonist in development for once-daily treatment of T2DM...
  29. ncbi request reprint Replacing SUs with incretin-based therapies for type 2 diabetes mellitus: challenges and feasibility
    Filip K Knop
    Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Niels Andersens Vej 65, DK 2900 Hellerup, Denmark
    IDrugs 11:497-501. 2008
    ..This feature review focuses on the challenges and feasibilities of replacing SU with incretin-based therapy in patients with T2DM...
  30. ncbi request reprint Increased postprandial responses of GLP-1 and GIP in patients with chronic pancreatitis and steatorrhea following pancreatic enzyme substitution
    Filip K Knop
    Dept of Internal medicine F, Gentofte Hospital, Univ of Copenhagen, Niels Andersens Vej 65, DK 2900 Hellerup, Denmark
    Am J Physiol Endocrinol Metab 292:E324-30. 2007
    ..These results suggest that the secretion of GLP-1 and GIP is under influence of the digestion and absorption of nutrients in the small intestine and that PES increases insulin secretion...
  31. ncbi request reprint The insulinotropic effect of GIP is impaired in patients with chronic pancreatitis and secondary diabetes mellitus as compared to patients with chronic pancreatitis and normal glucose tolerance
    Filip K Knop
    Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Denmark
    Regul Pept 144:123-30. 2007
    ..The incretin effect is reduced and the insulinotropic effect of the incretin hormone glucose-dependent insulinotropic polypeptide (GIP) is abolished in patients with type 2 diabetes mellitus (T2DM)...
  32. ncbi request reprint No hypoglycemia after subcutaneous administration of glucagon-like peptide-1 in lean type 2 diabetic patients and in patients with diabetes secondary to chronic pancreatitis
    Filip K Knop
    Department of Internal Medicine F, Gentofte Hospital, Hellerup, Denmark
    Diabetes Care 26:2581-7. 2003
    ..4 +/- 1.1 according to homeostasis model assessment (HOMA). In this study, we investigated diabetic patients with normal or close to normal insulin sensitivity...
  33. ncbi request reprint Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state?
    Filip K Knop
    Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
    Diabetes 56:1951-9. 2007
    ..These results suggest that the reduced incretin effect is not a primary event in the development of type 2 diabetes, but rather a consequence of the diabetic state...
  34. ncbi request reprint [GLP-1-based treatment of type 2 diabetes mellitus]
    Filip Krag Knop
    Vilsbøll Gentofte Hospital, Medicinsk afdeling F
    Ugeskr Laeger 169:2095-9. 2007
    ..GLP-1-based therapy results in HbA1c reductions of approximately 1 percent point, and the lack of serious side effects and the low risk of hypoglycaemic episodes are unique traits...
  35. doi request reprint Four weeks of near-normalization of blood glucose has no effect on postprandial GLP-1 and GIP secretion, but augments pancreatic B-cell responsiveness to a meal in patients with Type 2 diabetes
    P V Højberg
    Department of Endocrinology, Hvidovre Hospital, Hvidovre, Denmark
    Diabet Med 25:1268-75. 2008
    ..The aim of the present study was to investigate whether 4 weeks of near-normalization of blood glucose (BG) improves incretin hormone secretion and pancreatic B-cell function during a mixed meal...
  36. ncbi request reprint Incretins, insulin secretion and Type 2 diabetes mellitus
    T Vilsbøll
    Department of Internal Medicine F, Gentofte University Hospital, Gentofte, Denmark
    Diabetologia 47:357-66. 2004
    ..Several GLP-1 analogues are currently in clinical development and the reported results are, so far, encouraging...
  37. ncbi request reprint Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus
    F K Knop
    Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Niels Andersens Vej 65, DK 2900, Hellerup, Denmark
    Diabetologia 50:797-805. 2007
    ..We investigated glucagon responses during OGTT and isoglycaemic i.v. glucose infusion, respectively, to further elucidate the mechanisms behind the glucose intolerance in patients with type 2 diabetes...
  38. doi request reprint Reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity, and high-calorie diet impairs the incretin effect in healthy subjects
    K B Hansen
    Department of Clinical Physiology, Glostrup Hospital, University of Copenhagen, Nordre Ringvej 57, DK 2600 Glostrup, Denmark
    J Clin Endocrinol Metab 95:3309-17. 2010
    ..We investigated whether reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity, and high-calorie diet in healthy young males would impair the incretin effect...
  39. doi request reprint Near normalisation of blood glucose improves the potentiating effect of GLP-1 on glucose-induced insulin secretion in patients with type 2 diabetes
    P V Højberg
    Department of Endocrinology, Hvidovre Hospital, Kettegaards Alle 30, 2650 Hvidovre, Denmark
    Diabetologia 51:632-40. 2008
    ..We investigated whether 4 weeks of near normalisation of blood glucose (BG) improves the potentiation of glucose-stimulated insulin secretion by GLP-1...
  40. doi request reprint Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes
    P V Højberg
    Department of Endocrinology, Hvidovre Hospital, Kettegaards Alle 30, DK 2650 Hvidovre, Denmark
    Diabetologia 52:199-207. 2009
    ..The aim of the present study was to investigate whether 4 weeks of near-normalisation of the blood glucose level could improve insulin responses to GIP and GLP-1 in patients with type 2 diabetes...
  41. doi request reprint Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists
    K B Hansen
    Department of Clinical Physiology, Glostrup Hospital, University of Copenhagen, Nordre Ringvej, Copenhagen, Denmark
    Int J Clin Pract 63:1154-60. 2009
    ..In this review, the available data on the two drugs are presented and discussed...
  42. pmc The alpha-cell as target for type 2 diabetes therapy
    Mikkel Christensen
    Diabetes Research Division, Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Denmark
    Rev Diabet Stud 8:369-81. 2011
    ..At present, available pharmacological agents based on the glucose-dependent glucagonostatic effects of GLP-1 represent the most favorable way to apply constraints to the alpha-cell in type 2 diabetes...
  43. pmc The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action
    Kristine J Hare
    Department of Biomedical Sciences, The Panum Institute, University of Copenhagen, Copenhagen, Denmark
    Diabetes 59:1765-70. 2010
    ..The aim of this research was to quantify the glucagonostatic contribution to the glucose-lowering effect of GLP-1 infusions in patients with type 2 diabetes...
  44. ncbi request reprint Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects
    T Vilsbøll
    Department of Internal Medicine F, Gentofte Hospital, DK 290 Hellerup, Denmark
    J Clin Endocrinol Metab 88:220-4. 2003
    ..The impaired incretin response seen after ingestion of a standard breakfast meal must therefore be caused by a decreased secretion of GLP-1 in type 2 diabetic patients...
  45. doi request reprint The T allele of rs7903146 TCF7L2 is associated with impaired insulinotropic action of incretin hormones, reduced 24 h profiles of plasma insulin and glucagon, and increased hepatic glucose production in young healthy men
    K Pilgaard
    Steno Diabetes Center, Niels Steensens Vej 1, Gentofte, Denmark
    Diabetologia 52:1298-307. 2009
    ..We studied the physiological, metabolic and hormonal mechanisms underlying the elevated risk of type 2 diabetes in carriers of TCF7L2 gene...
  46. pmc Therapy for obesity based on gastrointestinal hormones
    Jonatan I Bagger
    Diabetes Research Division, Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Denmark
    Rev Diabet Stud 8:339-47. 2011
    ..This review discusses the effects of the incretin-based therapies in obesity, and provides an overview of intestinal peptides with promising effects as potential new treatments for obesity...
  47. doi request reprint Glucagon-like peptide-1, glucose homeostasis and diabetes
    Jens J Holst
    Department of Biomedical Sciences, The Panum Institute, University of Copenhagen, DK 2200 Copenhagen N, Denmark
    Trends Mol Med 14:161-8. 2008
    ..The pathophysiological basis the clinical use of these therapeutics is reviewed here...
  48. doi request reprint The incretin system and its role in type 2 diabetes mellitus
    Jens Juul Holst
    University of Copenhagen, Department of Biomedical Sciences, The Panum Institute, Blegdamsvej 3, DK 2200 Copenhagen N, Denmark
    Mol Cell Endocrinol 297:127-36. 2009
    ..Orally active DPP-4 inhibitors and the metabolically stable activators, exenatide (Byetta), are now on the market, and numerous clinical studies have shown that both principles are associated with durable antidiabetic activity...